In follow up to a post I did a couple days ago, The Financial Express reports that the MNC drug companies comprising the Organization of Pharmaceutical Producers of India (OPPI) clawed back at the domestic
Indian Pharmaceutical Alliance (IPA). The OPPI said there was a fundamental lack of understanding among the IPA in their opposition to all Indian drug patents granted after 2009 - purportedly objecting to these drugs as "incremental innovations".
The OPPI president, Ranjit Shahani, claimed that the IPA members are filing patents themselves for incremental improvements in many EU and US markets. He further stated that the IPA doesn't understand how drugs are brought to market around the world and that many of these "incremental improvements" were in fact providing more therapeutic benefits with fewer side effects.
The OPPI, that counts Novartis, Lilly, Merck, GSK and Pfizer amongst its members, said constant innovation is the only way to keep ahead of ever evolving diseases. The IPA says the MNCs are resorting to "evergreening" tactics as their pipelines are drying up and are merely looking to extend their patent life anyway they can. Meeeoooww!
Posted by Bruce Lehr April 14th 2010.